Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026850 (
muscular dystrophy
)
5,870
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Coenzyme Q
(10) (
CoQ
(10)) exists in human tissue, and is indispensable to mitochondrial enzymes of respiration.
CoQ
was administered to children with preclinical
muscular dystrophy
,
CoQ
enzymology was emphasized, and serum creatine phosphokinase, CPK, (ATP:creatine N-phosphotransferase, EC 2.7.3.2) was repeatedly monitored.A 40-week treatment of an infant, 1-2 years of age, reduced serum CPK (P < 0.001; total CPK assays, 76). A 40-week treatment of a boy, 3-5 years of age, reduced serum CPK (P < 0.01); treatment through 80 weeks reduced CPK (P < 0.001; total CPK assays, 118). This response of preclinical dystrophy to
CoQ
implies a deficiency of
CoQ
in skeletal muscle that was actually found previously by assay of the activity of the succinate dehydrogenase:coenzyme Q(10) reductase of the rectus abdominis. The relationships among a
CoQ
deficiency in muscle, serum CPK, and use of CPK in muscle are uncertain; however, restoration of
CoQ
enzyme activity in muscle by oral administration of
CoQ
could lead to increased use of CPK in muscle to form phosphocreatine from creatine and ATP, with a corresponding decrease in serum levels of CPK. The great excess of CPK in serum comes from deteriorating muscle in which CPK is below normal.
...
PMID:Effect of coenzyme Q on serum levels of creatine phosphokinase in preclinical muscular dystrophy. 452 74